ArticleDiabetes/metabolism research and reviews2025
Contributions of Clinical Obesity and Preclinical Obesity to the All-Cause Mortality Risk: Findings From the UK Biobank Cohort.
Article in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- BMI-Based and Clinical-Obesity Trajectories and Incident Cardiovascular Disease: A Prospective UK Biobank Study.Journal of clinical medicine · 2026Article
- The Clinical Outcomes of Preclinical and Clinical Obesity Across Multiple Cohorts.Obesity (Silver Spring, Md.) · 2026Article
- Diagnosis, staging and management of obesity: a synthesis of contemporary guidelines.Nature reviews. Endocrinology · 2026Review
- Long-term management of body weight and physiological mechanisms of weight regain.Journal of molecular cell biology · 2026Review
- Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States.Obesity (Silver Spring, Md.) · 2026Article
- Prevalence and comorbidity burden of clinical obesity in US adults.BMC public health · 2026Article
- Clinical Obesity Among Chinese Adults: Prevalence, Multimorbidity Burden, and Associations with Physical Activity.Nutrients · 2026Article
- Clinical evidence and biological mechanisms linking obesity to adverse outcomes in pediatric and adolescent acute lymphoblastic leukemia.Frontiers in oncology · 2026Review
- The lancet commission obesity categories, excess adiposity, and BMI discordance in urban Chinese adults: a cross-sectional survey in Beijing.Frontiers in nutrition · 2026Article
- Association of organ dysfunction trajectories and major adverse cardiovascular events using clinical obesity in UK Biobank.Frontiers in endocrinology · 2026Article
- Contributions of Clinical Obesity and Preclinical Obesity to the All-Cause Mortality Risk: Findings From the UK Biobank Cohort.Diabetes/metabolism research and reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe definition of clinical obesity was newly announced. The aim of our study was to investigate the association of preclinical obesity and clinical obesity either at baseline or determined during follow-ups with the risk of all-cause mortality.
methodsData were collected from 232,721 participants in the UK Biobank. Dysfunctions caused by obesity, in combination with an excess of anthropometric parameters, were used to diagnose clinical obesity. Participants were categorised into six clusters according to their baseline and follow-up dysfunction status. Time-dependent Cox proportional hazards regression was used to compare hazard ratios (HRs) for mortality across six clusters.
resultsIn a total of 19,704 deaths over a mean follow-up of 13.4 years, participants in Cluster 6 (clinical obesity at baseline; HR = 2.30, 95% CI: 2.16-2.44) and Cluster 3 (non-obesity with baseline dysfunctions; HR = 2.02, 95% CI: 1.85-2.20) exhibited the highest multivariable-adjusted mortality risk compared with participants without obesity and dysfunction at baseline and during follow-up (Cluster 1). This was followed by participants in Cluster 2 (non-obesity without baseline but with follow-up dysfunctions; HR = 1.99, 95% CI: 1.88-2.10), Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 1.97, 95% CI: 1.87-2.07), and Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 1.15, 95% CI: 1.09-1.22). Subgroup analyses showed consistently higher mortality risks in Cluster 6 across various demographics, notably among individuals with higher educational qualifications.
conclusionsClinical obesity was significantly associated with elevated all-cause mortality risk. These findings underscore the importance of early screening and intervention for dysfunctions in patients with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.